{"id":"NCT00883779","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","officialTitle":"A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2009-04-20","resultsPosted":"2015-12-14","lastUpdate":"2015-12-14"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Platinum chemotherapy (cisplatin or carboplatin)","otherNames":[]},{"type":"DRUG","name":"erlotinib [Tarceva]","otherNames":[]},{"type":"DRUG","name":"gemcitabine","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer. Patients will be randomized to receive gemcitabine (1250mg/m2 iv) on days 1 and 8, and cisplatin (75mg/m2) or carboplatin (5xAUC)on day 1, followed by Tarceva 150mg/day or placebo from day 15 to day 28 of each 4 week cycle for a total of 6 cycles,then followed by Tarceva or placebo monotherapy.The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Median Progression Free Survival (PFS) Time","timeFrame":"Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])","effectByArm":[{"arm":"Placebo","deltaMin":6,"sd":null},{"arm":"Erlotinib","deltaMin":7.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":26,"countries":["China","Hong Kong","Indonesia","Philippines","South Korea","Taiwan","Thailand"]},"refs":{"pmids":["23782814"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":76,"n":222},"commonTop":["Neutropenia","Rash","Anaemia","Nausea","Decreased appetite"]}}